Comparison

Reserpine

Item no. CS-1913-100mg
Manufacturer ChemScene
Amount 100mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 50-55-5
Available
CAS
50-55-5
Purity
>98%
Formula
C33H40N2O9
MWt
608.68
Solubility
DMSO : 7 mg/mL (11.50 mM; Need ultrasonic)
Clinical Information
Launched
Pathway
Membrane Transporter/Ion Channel; Autophagy
Target
Monoamine Transporter; Autophagy
Biological Activity
Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). IC50 & Target: VMAT2[1] In Vitro: Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). Reserpine displays a significant effect on the density of dopamine D1 receptors (F2, 12=8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change[1]. IC50 values of 43.9 and 54.9 uM are obtained after 1 day of treatment with Reserpine in JB6 P+ and HepG2-C8 cells, respectively. Reserpine induces luciferase activity in a dose-dependent manner at concentrations ranging from 5 to 50 uM, and no significant induction is observed at concentrations lower than 5 uM. Results demonstrate that Reserpine (2.5 to 10 uM) also increases the protein expression of Nrf2, HO-1, and NQO1. Reserpine at concentrations of 2.5 to 10 uM decreases the mRNA expression of DNMT1, DNMT3a, and DNMT3b in a concentration-dependent manner in JB6 P+ cells after 7 days of treatment. Reserpine at 10 uM generates a significant difference for DNMT3a expression (p<0.05)[2]. In Vivo: Withdrawal (48 h) from chronic (14-day) but not acute Reserpine administration in a dose of 0.2 mg/kg i.p. produces a significant reduction of the immobility time (F2, 18=3.68, p<0.05), but increases the climbing time (F2, 18=4.48, p<0.02), and does not change the swimming time (F2, 18=1.78; NS) in the forced swim test (FST) in rats[1]. Reserpine at a dose of 5 mg/kg body weight produces significant increase in the urinary excretion profile of vanillylmandelic acid (VMA) compare to control animals. The amount of 5-hydroxyindoleacetic acid (5-HIAA) excreted in animals treated with Reserpine is found to be more than in the control. Dose dependent hypotension is observed with Reserpine. Reserpine at doses of 0.5, 1, 5, 10 and 15 ug/kg produce significant (p<0.01) reduction in blood pressure compare to control[3].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close